Earnings Call · Q2 FY2023·2023-08-14

Q2 23EPS -33.33%·Rev n/aQ1 23EPS +16.67%·Rev n/aQ4 22EPS +7.22%·Rev n/aQ3 22EPS -9.76%·Rev n/a⚠ consensus missing

ATOSSA THERAPEUTICS, INC. ATOS

Eric Van Zanten — Vice President of Investor Relations

Steven Quay — Chief Executive Officer

Greg Weaver — Chief Financial Officer

−8.3%1d on move date−8.8% vs SPY3d−15.5%5d−15.2%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ATOS calls or request research access.

More ATOS calls Browse calls Request research access